Opipramol

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Summary

Opipramol is a medication to treat general anxiety and somatoform disorders.

Generic Name
Opipramol
DrugBank Accession Number
DB12930
Background

Opipramol has been used in trials studying the treatment of Dementia, Depression, Schizophrenia, Anxiety Disorders, and Psychosomatic Disorders.

Type
Small Molecule
Groups
Investigational
Structure
Thumb
Weight
Average: 363.505
Monoisotopic: 363.231062566
Chemical Formula
C23H29N3O
Synonyms
  • Opipramol

Pharmacology

Indication

Not Available

Pharmacology
Reduce drug development failure rates
Build, train, & validate machine-learning models
with evidence-based and structured datasets.
See how
Build, train, & validate predictive machine-learning models with structured datasets.
See how
Associated Conditions
Contraindications & Blackbox Warnings
Contraindications
Avoid life-threatening adverse drug events
Improve clinical decision support with information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.
Learn more
Avoid life-threatening adverse drug events & improve clinical decision support.
Learn more
Pharmacodynamics

Not Available

Mechanism of action
Not Available
Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism
Not Available
Route of elimination

Not Available

Half-life

Not Available

Clearance

Not Available

Adverse Effects
Adverseeffects
Improve decision support & research outcomes
With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates.
Learn more
Improve decision support & research outcomes with our structured adverse effects data.
Learn more
Toxicity

Not Available

Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
1,2-BenzodiazepineThe risk or severity of adverse effects can be increased when 1,2-Benzodiazepine is combined with Opipramol.
AcarboseOpipramol may decrease the hypoglycemic activities of Acarbose.
AcebutololOpipramol may decrease the antihypertensive activities of Acebutolol.
AceclofenacThe risk or severity of gastrointestinal bleeding can be increased when Opipramol is combined with Aceclofenac.
AcemetacinThe risk or severity of gastrointestinal bleeding can be increased when Opipramol is combined with Acemetacin.
AcenocoumarolThe risk or severity of bleeding can be increased when Opipramol is combined with Acenocoumarol.
AcetazolamideThe risk or severity of adverse effects can be increased when Acetazolamide is combined with Opipramol.
AcetohexamideOpipramol may decrease the hypoglycemic activities of Acetohexamide.
AcetophenazineThe serum concentration of Opipramol can be increased when it is combined with Acetophenazine.
Acetylsalicylic acidThe risk or severity of gastrointestinal bleeding can be increased when Opipramol is combined with Acetylsalicylic acid.
Interactions
Identify potential medication risks
Easily compare up to 40 drugs with our drug interaction checker.
Get severity rating, description, and management advice.
Learn more
Food Interactions
Not Available

Products

Products2
Drug product information from 10+ global regions
Our datasets provide approved product information including:
dosage, form, labeller, route of administration, and marketing period.
Access now
Access drug product information from over 10 global regions.
Access now
Product Ingredients
IngredientUNIICASInChI Key
Opipramol hydrochlorideB49OBI656M909-39-7DLTOEESOSYKJBK-UHFFFAOYSA-N

Categories

ATC Codes
N06AA05 — Opipramol
Drug Categories
Chemical TaxonomyProvided by Classyfire
Description
This compound belongs to the class of organic compounds known as dibenzazepines. These are compounds with two benzene rings connected by an azepine ring. Azepine is an unsaturated seven-member heterocycle with one nitrogen atom replacing a carbon atom.
Kingdom
Organic compounds
Super Class
Organoheterocyclic compounds
Class
Benzazepines
Sub Class
Dibenzazepines
Direct Parent
Dibenzazepines
Alternative Parents
Alkyldiarylamines / N-alkylpiperazines / Azepines / Benzenoids / Trialkylamines / 1,2-aminoalcohols / Azacyclic compounds / Primary alcohols / Organopnictogen compounds / Hydrocarbon derivatives
Substituents
1,2-aminoalcohol / 1,4-diazinane / Alcohol / Alkanolamine / Alkyldiarylamine / Amine / Aromatic heteropolycyclic compound / Azacycle / Azepine / Benzenoid
Molecular Framework
Aromatic heteropolycyclic compounds
External Descriptors
Not Available
Affected organisms
Not Available

Chemical Identifiers

UNII
D23ZXO613C
CAS number
315-72-0
InChI Key
YNZFUWZUGRBMHL-UHFFFAOYSA-N
InChI
InChI=1S/C23H29N3O/c27-19-18-25-16-14-24(15-17-25)12-5-13-26-22-8-3-1-6-20(22)10-11-21-7-2-4-9-23(21)26/h1-4,6-11,27H,5,12-19H2
IUPAC Name
2-[4-(3-{2-azatricyclo[9.4.0.0^{3,8}]pentadeca-1(15),3,5,7,9,11,13-heptaen-2-yl}propyl)piperazin-1-yl]ethan-1-ol
SMILES
OCCN1CCN(CCCN2C3=CC=CC=C3C=CC3=CC=CC=C23)CC1

References

General References
  1. DIMDI Drug Product Information: Opipramol AbZ film-coated tablets [Link]
PubChem Compound
9417
PubChem Substance
347829075
ChemSpider
9046
BindingDB
50170636
RxNav
7674
ChEBI
94614
ChEMBL
CHEMBL370753
ZINC
ZINC000021981303
PharmGKB
PA144614922
Wikipedia
Opipramol

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
3TerminatedTreatmentAnxiety Disorders / Dementia / Depression / Psychosomatic Disorders / Schizophrenia1
0Unknown StatusTreatmentSubstance Abuse1
Not AvailableEnrolling by InvitationNot AvailableAltered Mental Status / Cardiovascular Disease (CVD) / Cardiovascular Risk / High Blood Pressure (Hypertension) / Sleep Apnea / Sleep Bruxism / Sleep disorders and disturbances / Temporomandibular Disorders / Thyroid Dysfunction1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
FormRouteStrength
Tablet
Pill
Tablet, coatedOral
Tablet, film coatedOral100 MG
Tablet, coatedOral50 MG
Tablet, film coatedOral
Tablet, film coatedOral50 MG
Tablet, film coatedOral150 MG
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.105 mg/mLALOGPS
logP3.13ALOGPS
logP3.24ChemAxon
logS-3.5ALOGPS
pKa (Strongest Acidic)15.59ChemAxon
pKa (Strongest Basic)7.86ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count4ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area29.95 Å2ChemAxon
Rotatable Bond Count6ChemAxon
Refractivity114.06 m3·mol-1ChemAxon
Polarizability42.65 Å3ChemAxon
Number of Rings4ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Predicted ADMET Features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Drug created on October 21, 2016 01:22 / Updated on June 12, 2021 10:54